HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Haïk, S. Articles by Alpérovitch, A. Search for Related Content PubMed PubMed Citation Articles by Haïk, S. Articles by Alpérovitch, A. Related Collections Prion All Clinical trials Clinical trials Observational study (Cohort, Case control) Prion disease; see Infections/prion

Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects

From Raymond Escourolle Neuropathology Laboratory (Drs. Haïk, Sazdovitch, Faucheux, and Hauw), French National Reference Center for Creutzfeldt–Jakob Diseases (Drs. Haïk and Brandel), INSERM U360 (Drs. Haïk, Brandel, Sazdovitch, Delasnerie-Lauprêtre, Faucheux, Hauw, and Alpérovitch, D. Salomon), Pharmacovigilance Center, Pharmacology Laboratory (Dr. Soubrié), Salpêtrière Hospital, and Central Biochemistry Laboratory (Dr. Laplanche), Lariboisière Hospital, Paris, and AFSSAPS (Drs. Belorgey and Boher), Saint-Denis, France.

Address correspondence and reprint requests to Dr. S. Haïk, Raymond Escourolle Neuropathology Laboratory, INSERM U360, Salpêtrière Hospital, 47, bd de l’Hôpital, 75651 Paris Cedex 13, France; e-mail: haik{at}chups.jussieu.fr

Quinacrine has been reported as an antiprion agent and proposed as an immediately applicable treatment for Creutzfeldt–Jakob disease (CJD). The authors report the results of an open compassionate procedure to which 32 CJD patients had access. In some genotypic subgroups, a slight but nonsignificant increase in survival was observed, likely due to biased inclusion of long-term surviving patients. There was no pathologic evidence of a beneficial effect of quinacrine treatment.

Received June 30, 2004. Accepted in final form August 13, 2004.

This article has been cited by other articles:

				S. Haik, D. Galanaud, M. G. Linguraru, K. Peoc'h, N. Privat, B. A. Faucheux, N. Ayache, J.-J. Hauw, D. Dormont, and J.-P. Brandel In Vivo Detection of Thalamic Gliosis: A Pathoradiologic Demonstration in Familial Fatal Insomnia Arch Neurol, April 1, 2008; 65(4): 545 - 549. [Abstract] [Full Text] [PDF]

				S. Cronier, V. Beringue, A. Bellon, J.-M. Peyrin, and H. Laude Prion Strain- and Species-Dependent Effects of Antiprion Molecules in Primary Neuronal Cultures J. Virol., December 15, 2007; 81(24): 13794 - 13800. [Abstract] [Full Text] [PDF]

				S. Webb, T. Lekishvili, C. Loeschner, S. Sellarajah, F. Prelli, T. Wisniewski, I. H. Gilbert, and D. R. Brown Mechanistic Insights into the Cure of Prion Disease by Novel Antiprion Compounds J. Virol., October 1, 2007; 81(19): 10729 - 10741. [Abstract] [Full Text] [PDF]

				C. Korth and P. J. Peters Emerging pharmacotherapies for creutzfeldt-jakob disease. Arch Neurol, April 1, 2006; 63(4): 497 - 501. [Abstract] [Full Text] [PDF]

				J. Benito-Leon, S. Haik, and J.-P. Brandel Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects Neurology, May 24, 2005; 64(10): 1824 - 1824. [Full Text] [PDF]

Correspondence: